AOD9604 (Fragment 176-191): what the published research shows

AOD9604, also written AOD-9604 and known as hGH fragment 176-191 or Anti-Obesity Drug 9604, is a synthetic peptide corresponding to the C-terminal region of human growth hormone, residues 176 through 191. It sits in the pharmacological class of short-chain peptides — molecules that occupy a niche between small-molecule drugs and large proteins — and it is one of the unapproved compounds that the sports-medicine literature groups under the heading of a parallel "gray market" operating largely outside regulatory oversight [1][2]. The published work on this fragment centres on growth hormone receptor and lipolytic signalling in adipose tissue, and on the metabolic endpoints that follow from it.

What follows is a summary of the published research record: which mechanisms have been probed, in which models, and where the evidence stops. Where a finding comes from animal or in vitro work rather than human work, that is stated plainly. Nothing here is a dosing recommendation, and no outcome is promised.

Research Studies

AOD9604 and its identification as a growth hormone fragment

The compound is defined by its relationship to the parent hormone rather than by a novel scaffold. It is the 176-191 fragment of human growth hormone, a 16-residue C-terminal sequence, and the literature refers to it interchangeably as AOD9604, AOD-9604 and hGH fragment 176-191. The review literature that surveys peptide therapies marketed directly to patients lists AOD-9604 among the prominent unapproved peptides, alongside its pharmacological mechanism, safety profile and regulatory status as the three axes of interest [1][2].

That framing matters for how the rest of the evidence should be read. A fragment of a larger hormone is not automatically a smaller version of that hormone: the research question is whether the truncated sequence retains, loses or changes the activity of the full-length protein, and the published work on this fragment addresses that question in specific tissue models rather than in general.

AOD9604 and lipolytic activity in adipose tissue models

The core of the research interest in this fragment is lipolysis — the mobilisation of stored fat — and the work has been conducted principally in adipocyte and animal models. The fragment was developed under the anti-obesity designation reflected in its name, and the mechanistic rationale in the literature is that a C-terminal growth hormone fragment can act on fat tissue without carrying the full range of activities associated with intact growth hormone.

Two features of this evidence base should be kept in view. First, the models are predominantly preclinical; adipocyte preparations and animal systems do not translate directly to human metabolic outcomes. Second, the review literature that catalogues this compound treats it as unapproved, meaning it has not passed the regulatory evaluation of safety and efficacy that approved peptide drugs undergo [1][2]. A mechanistic signal in a cell or animal model and a demonstrated clinical effect are different categories of claim, and the published record on this fragment supports the former more strongly than the latter.

AOD9604 and growth hormone receptor signalling

Because the fragment derives from growth hormone, the receptor question is central: whether and how the truncated sequence engages growth hormone receptor signalling. The review coverage of unapproved peptides positions AOD-9604 within a discussion of pharmacological mechanisms, which is where the receptor-level work belongs [1][2]. The relevant distinction in the literature is between activity mediated through the growth hormone receptor and metabolic effects that may not require the full receptor repertoire of the parent hormone.

This is an area where the published record is mechanistic rather than clinical. Receptor-binding and signalling experiments establish what a peptide can do at a target; they do not establish what it does in a whole organism over time, and they do not establish safety. Both of those require separate work, and the review literature's inclusion of safety profile and regulatory status as distinct categories reflects that separation [1][2].

AOD9604 and metabolic endpoints in animal models

Animal work on this fragment has examined metabolic endpoints — the kind of measures used to assess fat mass and energy handling — and this is the layer of evidence most often cited when the compound is discussed. It is also the layer most often over-read. Findings generated in animal models describe those models; they are hypothesis-generating with respect to human physiology, not confirmatory.

The review literature that surveys this compound does not present it as an established therapeutic, but as an unapproved peptide marketed directly to patients [1][2]. That is the correct evidentiary frame for the animal data as well: a body of preclinical observation attached to a compound whose clinical status remains unapproved.

AOD9604 and the comparison with intact growth hormone

A recurring theme in the research is the contrast between the fragment and full-length growth hormone. The table below sets out the comparison as the literature frames it, without asserting equivalence in either direction.

The review literature draws the approved/unapproved line explicitly, describing a rigorous approval process that evaluates both safety and efficacy for approved peptide drugs and a parallel gray market for compounds that have not undergone it [1][2]. The fragment sits on the unapproved side of that line.

AOD9604 and the regulatory and gray-market context

The most consistent thing the published literature says about AOD-9604 is about its status rather than its activity. It is named among the prominent unapproved peptides marketed direct to patients, and the review's stated objective is to present pharmacological mechanisms, safety profiles and regulatory status for exactly this class of compound [1][2].

That context is not incidental to the science. Regulatory status determines what kind of evidence exists: an approved drug accumulates controlled human data because approval requires it, whereas an unapproved compound accumulates whatever the research literature and the market generate. For this fragment, the published record is weighted toward mechanism and preclinical model work, and the review literature treats the safety and efficacy questions as open [1][2].

AOD9604 and the limits of the current evidence

Three limits are visible in the record. The models are largely preclinical, so human metabolic outcomes are not established by the work summarised here. The compound is unapproved, so it has not been through the safety and efficacy evaluation that approved peptides undergo [1][2]. And the literature that surveys it is a review of mechanisms, safety profiles and regulatory status rather than a body of controlled trials reporting clinical endpoints [1][2].

None of that makes the mechanistic work uninteresting; it makes it mechanistic. A reader trying to establish what is known should treat the fragment's lipolytic and receptor-level findings as preclinical observations and the clinical questions as unanswered in the sources summarised here.

If you are reading this for personal health reasons

This material is sold for laboratory research use only, and we do not provide dosing or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician rather than relying on a research summary. The published record described above is a research record, not a treatment plan.

Sources

• [1] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v3
• [2] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v1
• [3] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://pubmed.ncbi.nlm.nih.gov/41966639/